Myriad Genetics, Inc. (MYGN) Expands Collaboration With AstraZeneca PLC (AZN) on Olaparib Phase 3 Clinical Trials
9/4/2013 12:45:13 AM
SALT LAKE CITY, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has entered into an expanded, nonexclusive global collaboration agreement with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program. Olaparib is an investigational orally active poly-ADP ribose polymerase (PARP) inhibitor being developed by AstraZeneca for the treatment of various tumor types including BRCA-mutated breast and ovarian cancers.
Help employers find you! Check out all the jobs and post your resume.